The first of many failures

So, we learn that the Trump admin could have used the WHO test for the virus but decided not to.

On Saturday Jan. 11 — a month and a half before the first Covid-19 case not linked to travel was diagnosed in the United States — Chinese scientists posted the genome of the mysterious new virus, and within a week virologists in Berlin had produced the first diagnostic test for the disease.

Soon after, researchers in other nations rolled out their own tests, too, sometimes with different genetic targets. By the end of February, the World Health Organization had shipped tests to nearly 60 countries.

But we were not one of the 60.

Why the United States declined to use the WHO test, even temporarily as a bridge until the Centers for Disease Control and Prevention could produce its own test, remains a perplexing question and the key to the Trump administration’s failure to provide enough tests to identify the coronavirus infections before they could be passed on, according to POLITICO interviews with dozens of viral-disease experts, former officials and some officials within the administration’s health agencies.

The slowness of the testing regimen — which, administration officials acknowledged this week, is still not producing enough tests to meet the national demand — was the first, and most sweeping, of many failures. So far there have been confirmed cases in at least 23 states, and at least 15 deaths, while the stock market plunged and an otherwise healthy economy braced for a major disruption.

And while Trump and his slaves kept on telling us it’s no big deal, hardly anybody has tested positive – without adding that that’s because we don’t have the tests.

“Please provide an explanation for why the Covid-19 diagnostic test approved by the World Health Organization was not used,” Sen. Patty Murray, the ranking Democrat on the Senate health committee, who represents the hard-hit state of Washington, asked in a 3½-page letter on the testing fiasco to Pence, Health Secretary Alex Azar, CDC director Robert Redfield, and Food and Drug Administration Commissioner Stephen Hahn.

No answer so far.

Comments are closed.